| Today's Big NewsFeb 7, 2023 |
|
April 3 - 4, 2023 | San Diego, CA Connect with leading communications professionals and have honest, open discussions about how to develop your career in the industry. Early Bird Rate Ends February 10th.
|
|
| By Nick Paul Taylor Roche is ready to wade into the increasingly ferocious fight for the paroxysmal nocturnal hemoglobinuria space. The Big Pharma’s subcutaneous contender matched AstraZeneca’s intravenous blockbuster incumbent Soliris in phase 3, positioning it to file for regulatory approvals around the world. |
|
|
|
By James Waldron Life sciences investment firm Syncona has blamed a “disappointing” drop in returns on plummeting share prices for British biotechs across its portfolio in December. |
By Nick Paul Taylor Racing toward a pivotal study, Rocket Pharmaceuticals has received a show of confidence from the FDA in the potential of its gene therapy treatment for a fatal genetic cardiac disease. |
By Annalee Armstrong Scales to assess Alzheimer’s disease are not nearly sensitive enough to pick up on clinically meaningful changes in progression for patients with early-stage disease. So do we throw out the scales and start over? A new study from the Alzheimer’s Association says no: we work with what we’ve got. |
|
Hear DDI expert, Dr. Brian Ogilvie, discuss the important takeaways from the draft global guideline in this new webinar... Read More & Register >>
|
|
By Gabrielle Masson Cell therapy biotech Neurona has laid off a quarter of its staff, or 18 of 68 employees, a spokesperson confirmed with Fierce Biotech. |
By Helen Floersh The new CAR design showed success in mouse models of glioma, bone cancer and lung cancer, making it a must-try in the clinic, the researchers said. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Kevin Dunleavy In a year of economic volatility and uncertainty—and one in which many other industries tanked—biopharma demonstrated its resilience. In all, 11 of the top 20 companies delivered market cap gains of at least 10%, led by Merck (45%), Vertex (33%) and Eli Lilly (32%). |
By Frank Diamond A statistically significant difference exists when it comes to what hospitals white and nonwhite patients are transported to by ambulance, according to a study published this week in Health Affairs. |
By Fraiser Kansteiner A coalition of cystic fibrosis patients and their families petitioned governments in South Africa, Brazil, India and Ukraine to either revoke or suspend Vertex patents surrounding the company’s tripartite drug Trikafta. |
By Andrea Park Just over a year after being recognized by the FDA for the potential “breakthrough” nature of its radiation therapy, RefleXion has gotten the go-ahead from the agency to begin rolling out the system across the U.S. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss what we can expect from the obesity market in 2023. We also recap the drugs approved last year. |
|
|---|
|
|
|
March 14-15, 2023 | San Francisco, CA Uncover flexible partnership models, licensing deals, M&A opportunities, and innovative deal structures to maximize potential and ensure a successful and profitable collaboration. Register today to secure our lowest rates!
|
|
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
